Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Vertex Pharmaceuticals Incorporated (VRTX) Return on equity
Vertex Pharmaceuticals Incorporated's return on equity over the twelve months to 30 June 2026 was 23.5%, up 1.0 percentage points from fiscal 2025 (22.5%). Over the past ten years it has ranged from −50.8% (fiscal 2015) to 64.7% (fiscal 2018); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of −57.7% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 22.5% | 25.69 |
| FY2024 | −3.15% | (26.14) |
| FY2023 | 23.0% | (4.68) |
| FY2022 | 27.7% | 2.74 |
| FY2021 | 24.9% | (11.78) |
| FY2020 | 36.7% | 14.34 |
| FY2019 | 22.4% | (42.37) |
| FY2018 | 64.7% | 49.15 |
| FY2017 | 15.6% | 24.81 |
| FY2016 | −9.22% | 41.59 |
Against its own ten years
Low −50.8%
High 64.7%
Ten-year median
22.5%
Current reading's percentile
55
Return on equity against peers
| Company | Return on equity |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | 96.6% |
| ARGX argenex SE compare | 27.1% |
| VRTX Vertex Pharmaceuticals Incorporated | 23.5% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 14.7% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 14.0% |
| RPRX Royalty Pharma PLC compare | 8.42% |
| MRNA Moderna, Inc. compare | −39.0% |
| RVMD Revolution Medicines, Inc. compare | −79.1% |
| INSM Insmed, Inc. compare | −87.2% |
| Biotechnology industry median | −57.7% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement